Blog
RSS FeedPosted by Michael Wonder on 12 Mar 2025
ACCRUFeR (ferric maltol) is now available in Canada as a prescription oral treatment for iron deficiency anaemia
11 March 2025 - ACCRUFeR is the only oral iron therapy approved as a prescription drug in Canada. ...
Posted by Michael Wonder on 11 Mar 2025
Health Canada authorises Lazcluze (lazertinib) in combination with Rybrevant (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
10 March 2025 - Phase 3 MARIPOSA study showed Lazcluze plus Rybrevant significantly improved progression-free survival, reducing the risk of ...
Posted by Michael Wonder on 08 Mar 2025
Acarizax approved in Canada for treatment of young children
7 March 2025 - ALK today announced that Health Canada has approved ALK’s Acarizax tablet for use in children, aged ...
Posted by Michael Wonder on 07 Mar 2025
Ferring receives Health Canada approval for Rebyota (faecal microbiota, live)
6 March 2025 - A novel first in class microbiome restoration therapy for the prevention of recurrence of C. difficile infection. ...
Posted by Michael Wonder on 05 Mar 2025
Skyrizi (risankizumab) now available for moderately to severely active ulcerative colitis, expanding AbbVie's portfolio across inflammatory bowel disease
4 March 2025 - Skyrizi is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and ...
Posted by Michael Wonder on 03 Mar 2025
Canada’s Drug Agency publishes new guidance for rare disease registries in Canada
28 February 2025 - On Rare Disease Day — a global event dedicated to raising awareness for the millions of ...
Posted by Michael Wonder on 01 Mar 2025
Bimzelx (bimekizumab) negotiations with pCPA concluded successfully following positive CDA and INESSS recommendations for adults with active psoriatic arthritis and adults with active ankylosing spondylitis
28 February 2025 - Positive CDA and INESSS reimbursement recommendations are an important step towards public access to Bimzelx, the first ...
Posted by Michael Wonder on 28 Feb 2025
Government of Canada signs Pharmacare agreement with Manitoba to improve affordable access to medications
27 February 2025 - Additional agreement will improve access and affordability of drugs for rare diseases. ...
Posted by Michael Wonder on 27 Feb 2025
Kashiv BioSciences obtains marketing authorisation for pegfilgrastim injection from Health Canada
25 February 2025 - Kashiv BioSciences today announced that Health Canada has granted marketing authorisation for its pegfilgrastim injection, enabling its ...
Posted by Michael Wonder on 22 Feb 2025
Health Canada authorizes Itovebi (inavolisib film-coated tablets), a targeted treatment for advanced hormone receptor-positive, HER2 negative breast cancer with a PIK3CA mutation
19 February 2025 - The approval provides another treatment option for breast cancer patients with a PIK3CA mutation, one of the ...
Posted by Michael Wonder on 21 Feb 2025
Eylea HD pre-filled syringe with OcuClick dosing system granted marketing authorisation in Canada
20 February 2025 - Bayer is pleased to announce that Health Canada has granted marketing authorisation for Eylea HD (aflibercept injection ...
Posted by Michael Wonder on 14 Feb 2025
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance successfully finalise negotiations for Apretude for HIV-1 pre-exposure prophylaxis
13 February 2025 - ViiV Healthcare is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance ...
Posted by Michael Wonder on 14 Feb 2025
Novartis receives Health Canada approval for Fabhalta oral treatment for adult patients with paroxysmal nocturnal haemoglobinuria
13 February 2025 - Fabhalta is the first oral monotherapy for previously treated and treatment naïve adults with paroxysmal nocturnal haemoglobinuria. ...
Posted by Michael Wonder on 12 Feb 2025
Health Canada approves Merck's Keytruda (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
11 February 2025 - Approval is based on the Phase 3 KEYNOTE-671 trial. ...
Posted by Michael Wonder on 05 Feb 2025
Medexus and Ontario's Provincial Health Services successfully complete agreements for public reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
4 February 2025 - Medexus recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario ...